Literature DB >> 20544327

Management of malignant pleural effusions.

Mateen H Uzbeck1, Francisco A Almeida, Mona G Sarkiss, Rodolfo C Morice, Carlos A Jimenez, Georgie A Eapen, Marcus P Kennedy.   

Abstract

Malignant pleural effusions are a common clinical problem in patients with primary thoracic malignancy and metastatic malignancy to the thorax. Symptoms can be debilitating and can impair tolerance of anticancer therapy. This article presents a comprehensive review of pharmaceutical and nonpharmaceutical approaches to the management of malignant pleural effusion, and a novel algorithm for management based on patients' performance status.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20544327     DOI： 10.1007/S12325-010-0031-8

Source DB:  PubMed          Journal:  Adv Ther        ISSN： 0741-238X            Impact factor:   3.845


  11 in total

1.  Hemothorax: A Review of the Literature.

Authors:  Jacob Zeiler; Steven Idell; Scott Norwood; Alan Cook
Journal:  Clin Pulm Med       Date:  2020-01-10

2.  Long-term outcome of pleurodesis with OK-432 in metastatic breast cancer: a new risk model for success from an analysis of 75 cases.

Authors:  Nobuaki Matsubara; Kuniaki Itoh; Hirofumi Mukai; Shunji Nagai
Journal:  Int J Clin Oncol       Date:  2011-10-07       Impact factor: 3.402

3.  Interventional radiology and the care of the oncology patient.

Authors:  Siobhan B O'Neill; Owen J O'Connor; Max F Ryan; Michael M Maher
Journal:  Radiol Res Pract       Date:  2011-03-29

4.  A modified experimental model of malignant pleural disease induced by lung Lewis carcinoma (LLC) cells.

Authors:  Milena Marques Pagliarelli Acencio; Juliana Puka; Evaldo Marchi; Leila Antonangelo; Ricardo Mingarini Terra; Francisco Suso Vargas; Vera Luiza Capelozzi; Lisete Ribeiro Teixeira
Journal:  J Transl Med       Date:  2015-09-15       Impact factor: 5.531

Review 5.  Malignant pleural effusion: medical approaches for diagnosis and management.

Authors:  Hae-Seong Nam
Journal:  Tuberc Respir Dis (Seoul)       Date:  2014-05-29

6.  Interpretation of PET/CT findings in patients with advanced lung cancer who have undergone pleurodesis.

Authors:  Marcus Paulo Fernandes Amarante; Riad Naim Younes; Letícia Rigo; Marcelo Rocha de Sousa Cruz
Journal:  Ecancermedicalscience       Date:  2014-08-12

7.  The importance of serum and pleural fluid level of vascular endothelial growth factor (VEGF) and VEGF fluid/serum ratio in the differential diagnosis of malignant mesothelioma-related pleural effusion.

Authors:  Yakup Düzköprü; Zeynep Oruç; Muhammet A Kaplan; Refik Ülkü; Çetin Tanrıkulu; Derya Esmer; Ali Bırak; Mehmet Küçüköner; Zuhat Urakçı; Abdurrahman Işıkdoğan
Journal:  Contemp Oncol (Pozn)       Date:  2017-09-29

8.  Treatment of malignant effusion by oncolytic virotherapy in an experimental subcutaneous xenograft model of lung cancer.

Authors:  Stephanie Weibel; Elisabeth Hofmann; Thomas Christian Basse-Luesebrink; Ulrike Donat; Carolin Seubert; Marion Adelfinger; Prisca Gnamlin; Christina Kober; Alexa Frentzen; Ivaylo Gentschev; Peter Michael Jakob; Aladar A Szalay
Journal:  J Transl Med       Date:  2013-05-01       Impact factor: 5.531

9.  TLR2 in pleural fluid is modulated by talc particles during pleurodesis.

Authors:  Karolina Jankovicova; Katerina Kondelkova; Petr Habal; Ctirad Andrys; Jan Krejsek; Jiri Mandak
Journal:  Clin Dev Immunol       Date:  2012-12-10

10.  Silver nitrate versus tetracycline in pleurodesis for malignant pleural effusions; a prospective randomized trial.

Authors:  Seyed Abass Tabatabaei; Seyed Mozafar Hashemi; Ali Kamali
Journal:  Adv Biomed Res       Date:  2015-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.